Navigation Links
ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver

- Phase 1b Combination Data Highlight Favorable Tolerability and Additive Antiviral Activity of HCV-796 -

EXTON, Pa., April 13, 2007 /PRNewswire-FirstCall/ -- ViroPharma Incorporated today announced additional data from a Phase 1b study of HCV- 796, a unique, orally dosed hepatitis C virus (HCV) polymerase inhibitor at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL). This meeting is being held in Barcelona, Spain. These data on the antiviral activity and tolerability of twice daily HCV-796 in combination with pegylated interferon alfa-2b (peg-IFN) elaborate on previously presented data. HCV-796 is currently undergoing Phase 2 evaluation and is being co-developed with Wyeth Pharmaceuticals, a division of Wyeth .

These Phase 1b combination data demonstrate the additive antiviral effects of HCV-796 across multiple genotypes of hepatitis C virus, in treatment-naïve adult subjects with chronic hepatitis C infection. HCV-796 dosed twice daily plus peg-IFN displays clinical antiviral activity that is greater than that of HCV-796 or peg-IFN alone across all dose cohorts and tested HCV genotypes. Final safety and tolerability data show that HCV-796 is generally well tolerated when added to peg-IFN. Adverse events were generally consistent with known effects of interferons. No dose-limiting toxicities were observed across the range of HCV-796 study doses.

"In this Phase 1b study, HCV-796 provided added antiviral activity to that of pegylated interferon across multiple HCV genotypes and did so largely without altering interferon's tolerability profile," commented Colin Broom, ViroPharma's chief scientific officer. "The adverse events observed in patients on combination therapy were typical of those seen in patients on pegylated interferon alone. The antiviral activity of HCV-796, its strong tolerability profile, and its lack of dose limiting toxicities encou
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:2/27/2015)... , Feb. 27, 2015  Uroplasty, Inc. (NASDAQ: ... manufactures and markets innovative proprietary products to treat voiding ... 27th Annual ROTH Conference on Tuesday, March 10, 2015. ... Brett Reynolds , Chief Financial Officer, will present at ... on one at the conference at the Ritz Carlton ...
(Date:2/26/2015)... RnRMarketResearch.com adds Corneal Ulcers ... to its store. This report p provides an ... The report "Corneal Ulcers - Pipeline Review, H2 2014" ... Corneal Ulcers. Corneal Ulcers are primarily result of ... infections & fungal infections. The symptoms of the ...
(Date:2/26/2015)... 26, 2015  Mobility Ventures LLC, an AM General ... of America (NYSE: BAC ) that will ... of the revolutionary MV-1 - - the world,s first ... up to provide safe and comfortable transportation for all ... loan to purchase a new MV-1 vehicle at the ...
Breaking Medicine Technology:Uroplasty to Participate in the 27th Annual ROTH Conference 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3
... Pharmaceuticals, Inc. (Nasdaq: QCOR ) announced today that ... at 1:00 p.m. ET on Wednesday, November 3, 2010 at ... and Chief Executive Officer, will review the Company,s business strategy ... is by invitation only. A live audio and slides webcast ...
... AG (VSE: ICLL) today announced results from a Phase ... candidate (IC43) against infections with the bacterium Pseudomonas ... infections with increasing antibiotic resistance and hence a very ... controlled Phase II clinical trial (33 sites in 8 ...
Cached Medicine Technology:Intercell Reports Positive Results From Its Phase II Pseudomonas Aeruginosa Investigational Vaccine Study for Certain Hospital-Acquired Infections 2Intercell Reports Positive Results From Its Phase II Pseudomonas Aeruginosa Investigational Vaccine Study for Certain Hospital-Acquired Infections 3
(Date:2/28/2015)... The Classic Denture Center , ... special. Throughout all of March patients can receive ... service can help overall mouth health and ... may notice certain symptoms that suggest the denture teeth ... include: , 1.    Pain, clicking, and popping in the joints, ...
(Date:2/28/2015)... 28, 2015 A study out of ... gene therapy procedure for the treatment of a hereditary ... Authored by Dr. Robert MacLaren, professor of ... the Lancet Medical Journal on January 16, 2014 , ... rare genetic disorder that mostly affects men and leads ...
(Date:2/28/2015)... 2015 Dr. Perry Patel , ... residents, recently announced a special offer for the Zoom!® ... option for new and established patients at his Pismo Beach ... bright, white smile, Dr. Patel and his staff are ... down from the regular price of $450. , Zoom! ...
(Date:2/28/2015)... NY (PRWEB) February 28, 2015 On Thursday, ... Kits Make It Easy For Scammers To Steal Your Data ... can get their hands on a DIY phishing kit, or ... it also touched on another important point about how everyone’s ... kits are often implemented, “like compromising legitimate content management systems ...
(Date:2/28/2015)... Powermod ” was featured on NewsWatch as part of its ... and coolest technology products and services available to consumers. Scott ... conducted the review and shared with viewers how they provide ... a low battery and no way to charge a phone ... daily basis. Even when a person does have a charger, ...
Breaking Medicine News(10 mins):Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 4Health News:Solutions to Keep Phones Charged were Featured on NewsWatch Television on January 29, 2015 2
... vCJD is a rare, degenerative and fatal brain disorder. The ... or autopsy. Data from a recent study links // the ... transfusion. ,The first case of vCJD linked to ... that time, 17 people who had received blood donated from ...
... pulmonary disease, an often neglected disease of the respiratory system ... majority of people with the disease are smokers. Exposure to ... fires also comes into play in some cases. ,According ... it will be the third leading cause of death worldwide. ...
... cup of coffee at breakfast may be making an ... to determine how caffeine impacts blood sugar control and ... cups of instant coffee a day significantly impaired glucose ... studies have associated caffeine with decreased insulin sensitivity in ...
... attacks without chest pain are more often fatal. Chest pain ... chest pain //, some patients experience symptoms like fainting, shortness ... conducted a study to see how patients who have a ... recover. The study included information on 20,881 patients from 14 ...
... , that older men are not the only ones using ... (sildenafil) // users are men between ages 18 to 55. ... males, ages 18 and older, from 1998 to 2002. The ... group, with men older than 56 years receiving the majority ...
... children with hemophilia arthropathy, a severe form of hemophilia ... risk // than other children for developing osteoporosis ... hope in preventing osteoporosis from hitting these children, say ... impact activities than was previously advised by doctors. An ...
Cached Medicine News:
Round solid 10 mm wide lower plate. Open upper plate with inside diameter 8 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....
Utrata-like fine angled tips with gently curved shaft for performing capsulorhexis through tunnel incisions. Dull finish. Flat handle....
Gently curved shaft with 2 mm platform ideal for performing capsulorhexis through a tunnel incision. Flat handle with dull finish....
Straight shafts with 4 mm platform. Wide serrated handle with dull finish. Platform straight....
Medicine Products: